Radiopharm Theranostics Ltd ADR (RADX)
Radiopharm Theranostics Ltd ADR (NASDAQ: RADX) is a depositary receipt representing common stock in Radiopharm Theranostics Limited, a clinical-stage radiotherapeutics company focused on researching and developing radiopharmaceutical products for diagnostic and therapeutic applications. The company’s pipeline includes programs in brain metastasis, HER2-positive breast cancer, PD-L1 non-small cell lung cancer, pancreatic cancer, prostate cancer, and glioblastoma, with both diagnostic and therapeutic candidates under development. Its portfolio includes RAD101 through RAD602, covering multiple target areas and modalities. Radiopharm Theranostics has also entered into a strategic agreement with Lantheus Holdings, Inc. to support the clinical development of its radiopharmaceutical assets. The company was incorporated in 2021 and is based in Carlton, Australia.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-RADX
|
$5.07
|
14.6% Upside
|
Fair
|
$17.11
|
287.2% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
September 24, 2026
|
-1.5x
|
1.4x
|
4.4x
|
47.269 M
|
23.039 M
|
0.0%
|
70.2%
|
-9.4
|
—
|
79.6%
|
